A Phase 2/3 Trial of FG-4592 for Treatment of Anemia in Subjects With Lower Risk Myelodysplastic Syndrome
Phase of Trial: Phase II/III
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors FibroGen
- 09 May 2019 According to a FibroGen media release, open lable portion of this study is ongoing.
- 07 Aug 2018 According to a FibroGen media release, patient dosing is underway in this study.
- 03 Aug 2018 Status changed from not yet recruiting to recruiting.